Envisia Therapeutics

ENV515 is a proprietary, fully biodegradable PRINT (Particle Replication In Non-Wetting Templates) particle formulation of a prostaglandin analog, travoprost, with the potential for sustained intraocular pressure (IOP) reduction over as many as 6 months. In hypertensive beagles, a “rapid drop” in pressure was maintained over 8 months, Yerxa said, accounting for a 32% reduction in intraocular pressure (IOP). A phase 2a in cataractous glaucoma patients (n=20) is evaluating the compound in four doses (Travatan Z is being used in the non-study eye).

ENV515 is expected to enter phase 3 studies in Q1 2017.

ENV905 is being developed for postoperative inflammation. Data show a 3-4 week control of postop inflammation in rabbit eyes. The IND is expected some time in 2H 2015, and phase 3 studies are expected to begin in Q1 2017.

While “there are challenges in VEGF models,” Envisia is evaluating an extended-release bevacizumab compound, and is working on combination products for drug delivery through engineered nanoparticles.


Benjamin Yerxa

Benjamin Yerxa

Dr. Yerxa is President of Envisia Therapeutics, a spin out of Liquidia Technologies. Previously, he was the CSO for both Liquidia and Envisia and joined Liquidia from Clearside Biomedical.

View Full Profile